Sponsors (4)
The bill funds and modernizes the OTC monograph system—promising faster reviews, more OTC access, transparency, and reduced animal testing—while shifting significant costs and administrative burdens onto regulated firms (and potentially consumers) and introducing tradeoffs in evidentiary standards, confidentiality, and implementation complexity.
Patients, consumers, and the FDA benefit from a predictable, dedicated funding stream for OTC monograph activities (fee authorizations, revenue targets, and a clear start date), which should speed reviews, stabilize program budgeting, and improve FDA capacity to process OTC standards and orders.
Consumers (including seniors, children, and those with chronic conditions) stand to get faster and broader access to safe nonprescription drugs and improved labeling/decision aids because the bill encourages use of real‑world evidence and creates clearer switch pathways with predictable meetings and expectations.
Patients, industry, and policymakers gain greater transparency because the bill requires public reporting (Federal Register notices of fees, FDA reports on monograph actions, GAO supply‑chain assessments, and meeting minutes), improving oversight and predictability of regulatory actions.
Small manufacturers, contract facilities, hospitals, and ultimately consumers face higher costs because the bill raises fee revenue targets, allows one‑time and future upward fee adjustments, and begins fee collection in Oct 2025—costs that may be passed through to consumers.
Allowing broader evidence standards (real‑world evidence and nontraditional data) and faster approval pathways could lower premarket evidentiary thresholds for some products, increasing uncertainty about safety/effectiveness and shifting burdens to postmarket monitoring.
Expanded reporting, publication requirements, and new processes add administrative burden and likely costs for FDA and GAO (and for regulated firms to prepare disclosures), which could divert agency resources from direct review or enforcement unless staffing/resources are increased.
Based on analysis of 10 sections of legislative text.
Revises and extends OTC monograph user‑fee rules, fee timing/revenue calculations, reporting, testing standards for topical drugs (including sunscreen), and Rx‑to‑OTC procedures, effective Oct 1, 2025.
Introduced July 15, 2025 by James E. Banks · Last progress July 15, 2025
Updates and extends the FDA’s user-fee framework and regulatory procedures for over‑the‑counter (OTC) monograph drugs. It changes how facility fees are assessed and due for FY2026–FY2028 and beyond, requires expanded FDA reporting, sets evidence and testing standards for topical nonprescription drugs (including sunscreen), encourages non‑animal testing methods, creates clearer procedures for converting prescription drugs to nonprescription status, and sunsets the new statutory provisions in 2030–2031. Fees must begin to be assessed as of October 1, 2025.